Document Detail


Methylprednisolone inhibits increase of interleukin 8 and 6 during open heart surgery.
MedLine Citation:
PMID:  7614647     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
It has been reported that interleukin 8 (IL-8) and interleukin 6 (IL-6) are two of the chemical mediators causing myocardial injury. It is not clear whether treatment with corticosteroids in vitro in these patients can prevent the production of interleukin 8 and 6. This prospective study was conducted to investigate whether methylprednisolone (MP) pretreatment (30 mg.kg-1 before CPB and before declamping of aorta) influenced the production of IL-8 and 6 in the peripheral circulation in 27 patients undergoing elective coronary artery bypass surgery. The IL-8 and IL-6 concentrations were measured by ELISA kit. We also studied the effect of MP pretreatment on postoperative cardiac function. Serum concentration of IL-8 in non-MP-treated patients (37 +/- 44 pg.ml-1 preoperatively) increased to 169 +/- 86 pg.ml-1 60 min after declamping of the aorta (P < 0.001). The increase was greater than the increase from 22 +/- 8.9 pg.ml-1 to 52 +/- 35 pg.ml-1 in the MP-treated patients (P < 0.01). Serum IL-6 concentration in non-MP-treated patients increased from the preoperative value of 59 +/- 30 pg.ml-1 to 436 +/- 143 pg.ml-1 60 min after declamping of the aorta (P < 0.001). The increase was greater than the increase from 36 +/- 15 pg.ml-1 to 135 +/- 85 pg.ml-1 in the MP-treated patients (P < 0.01). Furthermore, postoperative cardiac index in MP-treated patients (3.6 +/- 1.1 L.min-1.m-2) was higher than 2.3 +/- 0.8 L.min-1.m-2 of non MP-treated patients (P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
T Kawamura; K Inada; H Okada; K Okada; R Wakusawa
Related Documents :
18930517 - Elevated granulocyte colony-stimulating factor levels predict treatment failure in pati...
18560257 - Biochemical markers for cardiovascular risk following treatment in endogenous cushing's...
11602907 - Differences in arterial and mixed venous il-6 levels: the lungs as a source of cytokine...
17452737 - Cytokines and c-reactive protein production in hip-fracture-operated elderly patients.
2971497 - Decreased iodine-123 imp caudate nucleus uptake in patients with huntington's disease.
3019597 - Plasma-free eicosapentaenoic acid/arachidonic acid ratio: a possible new coronary risk ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Canadian journal of anaesthesia = Journal canadien d'anesthésie     Volume:  42     ISSN:  0832-610X     ISO Abbreviation:  Can J Anaesth     Publication Date:  1995 May 
Date Detail:
Created Date:  1995-08-22     Completed Date:  1995-08-22     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8701709     Medline TA:  Can J Anaesth     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  399-403     Citation Subset:  IM    
Affiliation:
Department of Anesthesiology, Iwate Medical University, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiac Output / drug effects
Cardiopulmonary Bypass
Coronary Artery Bypass*
Creatine Kinase / blood
Heart / drug effects
Humans
Interleukin-6 / antagonists & inhibitors*,  blood
Interleukin-8 / antagonists & inhibitors*,  blood
Isoenzymes
Leukocyte Elastase
Methylprednisolone / administration & dosage,  therapeutic use*
Middle Aged
Myocardial Reperfusion
Pancreatic Elastase / blood
Premedication
Prospective Studies
Pulmonary Wedge Pressure / drug effects
Surgical Procedures, Elective
Chemical
Reg. No./Substance:
0/Interleukin-6; 0/Interleukin-8; 0/Isoenzymes; 83-43-2/Methylprednisolone; EC 2.7.3.2/Creatine Kinase; EC 3.4.21.36/Pancreatic Elastase; EC 3.4.21.37/Leukocyte Elastase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Secondary hyperparathyroidism shortens the action of vecuronium in patients with chronic renal failu...
Next Document:  Anaesthetic induction in a child with end-stage cardiomyopathy.